Skip to main content

fosfomycin (Fomicyt®)

 

Following a limited submission

AWMSG advice

Status: Recommended

Fosfomycin (Fomicyt®) is recommended as an option for use within NHS Wales for the treatment of the following infections in adults and children including neonates:

  • acute osteomyelitis;
  • complicated urinary tract infections;
  • nosocomial lower respiratory tract infections;
  • bacterial meningitis;
  • and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Fosfomycin (Fomicyt®) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections listed above, or when these alternative antibacterial agents have failed to demonstrate efficacy.

 Final Recommendation: fosfomycin (Fomicyt) 2710 (PDF, 362Kb)
 Appraisal Report: fosfomycin (Fomicyt) 2710 (PDF, 460Kb)

Medicine details

Medicine name fosfomycin (Fomicyt®)
Formulation 40 mg/ml powder for solution for infusion
Reference number 2710
Indication

Treatment of the following infections in adults and children including neonates:

  • acute osteomyelitis;
  • complicated urinary tract infections;
  • nosocomial lower respiratory tract infections;
  • bacterial meningitis;
  • and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above
Company Nordic Pharma UK Ltd
BNF chapter Infections
Submission type Limited
Status Recommended
Advice number 2710
NMG meeting date 09/09/2015
AWMSG meeting date 21/10/2015
Ratification by Welsh Government 17/11/2015
Date of issue 18/11/2015
Date of last review 02/04/2019
Follow AWTTC: